Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy

Multicentric Castleman disease (MCD) is a lymphopro-liferative opportunistic tumor occurring in HIV-patients strongly associated with the human herpesvirus (HHV)-8 and with high mortality rates [1]. Therapeutic options include lymphoma-type chemotherapy, virostatics and/or immunomodulators [2]. So far, no standard treatment exists because no randomized controlled trials can be performed due to the rarity of the disease [3]. Chemotherapy may further limit immune recovery and control of HHV-8, and thereby hamper remission of MCD.